Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non–small cell lung cancer

• Published in: Cancer Vol. 128; no. 4; pp. 708 - 718
• Main Authors: Li, Ning, Wang, Bao‐Xiao, Li, Jian, Shao, Yang, Li, Ming‐Tian, Li, Jian‐Jun, Kuang, Peng‐Peng, Liu, Zui, Sun, Tian‐Yu, Wu, Hui‐Qi, Ou, Wei, Wang, Si‐Yu
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 15.02.2022
• Subjects: Biomarkers; Biomarkers, Tumor - blood; Carcinoma, Non-Small-Cell Lung - blood; Carcinoma, Non-Small-Cell Lung - surgery; circulating tumor DNA (ctDNA); Circulating Tumor DNA - blood; Deoxyribonucleic acid; DNA; Health risks; Humans; Lead time; Lung cancer; Lung Neoplasms - blood; Lung Neoplasms - surgery; Medical imaging; Medical prognosis; Metastases; Minimal residual disease; Monitoring; Neoplasm Recurrence, Local - blood; Neoplasm Recurrence, Local - pathology; Non-small cell lung carcinoma; non–small cell lung cancer (NSCLC); Oncology; Patients; Peripheral blood; Prognosis; Prospective Studies; recurrence; Risk assessment; Small cell lung carcinoma; Surgery; Survival; Telemedicine; Tumors; recurrence; circulating tumor DNA (ctDNA); prognosis; non-small cell lung cancer (NSCLC); surgery

Background Circulating tumor DNA (ctDNA) has emerged as a noninvasive biomarker for dynamically monitoring tumors. However, published data on perioperative ctDNA in patients with operable non–small cell lung cancer (NSCLC) are currently limited. Methods This prospective study recruited 123 patients...